10/519427 ec'd POT/PTO 22 DEC 2004

Not Yet Known

BIANCHI, Marco

Herewith

PTO/S8/08A (02-03)
Approved for use through 04/30/2003. CMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application Number

First Named Inventor

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete If Known

Filing Date

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Art Unit Not Yet Known (Use as many sheets as necessary) **Examiner Name** Not Yet Known Sheet 1 Attorney Docket Number 1014-PCT-US

			U. S. PATENT D	OCUMENTS		
Examiner Initials*	Cite No.	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
umais	NO.	Number-Kind Code ² (1 broad)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear	
		US-				
		US-	1			
		US-	1			
		US-	†			
		US-				
		US-	 			
		US-	 			
	1	US-				
		US-	 			
		US-				
		US-	1			
		US-	1	-	 	
		US-	1			
		US-	1			
		US-	1	•		
		US-	1			
		US-	1		 	
		US-	1		<u> </u>	
	<u> </u>	US-				

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ Number ⁴ "Kind Code ⁶ (# known)	MM-DD-YYYY	V	Or Refevant Figures Appear	T
11(19	2	WO 00/47104 A2	08-17-2000	PICOWER INST MED RES		
	3	WO 01/89526 A 1	11-29-2001	Horth Shore Long Island Jordan Research Institute		
	9	WO 02/092004 A2	11-21-2002	HORTH SHORE-LONG GLAND JENISH RES. HS ITI.		
	10	WO 02/074301 A1	09-26-2002	Fink Mitchell P.		
•	13	WO 97/23611 A 2	07-03-1997	BULLERDIEK JOER		Г

Examiner Signature	Bruse D.	Him	Date Considered	3/30/06	

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usaip.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sarial number of the patent document. Kind of document of document with the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patenta, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/51946/ 3T12 Rec'd PON/PTO 2 2 DEC 2004

PTO/S8/088 (02-03)

	Approved for use through 04/30/2003, CMB 0651-0031
·	U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respon	The state of the s
<u> - Viner like i pretivoji, i reduction Act di 1995, no persons ere regulier in regone</u>	III IO 8 CONSCION Of information unless it contains a valid OMS control cumber.

Substin	de for form 1449/PTO				Complete if Known
				Application Number	Not Yet Known
			CLOSURE	Filing Date	Herewith
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	BIANCHI, Marco
	(Use as many she	ets es r	ocossan/i	Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet	2	of	2	Attorney Docket Number	1014-PCT-US

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	PCT International Search Report for BIANCHI, et al., Int'l Application No. PCT/IT2003/000265, Filed April 29, 2003, Dated November 13, 2003.	
BO }	4	FANG, et al; "The Significance of Changes in High Mobility Group-1 Protein mRNA Expression in Rats after Thermal Injury", Shock (Augusta, G.A.) United States APR, 2002; Vol. 17, No. 4, April 2002, Pgs. 329-333, XP009020804.	
	5	FAGES, et al; "Regulation of Cell Migration by Amphoterin", Journal of Cell Science, Essex, GB; Vol. 113, No. 4, February 2000, Pages 611-620, XP001070170.	
	6	MULLER, et al.; "The Double Life of HMGB1 Chromatin Protein: Architectural Factor and Extracellular Signal", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) Journal; Vol. 20, No. 16, August 15, 2001, Pages 4337-4340, XP002261324.	
	7	WANG, et al.; "HMGB1 as a late Mediator of Lethal Systemic Inflammation", American Journal of Respiratory and Critical care Medicine; Vol.164, No. 10, Part 1, November 15, 2001, Pages 1768-1773.	
T	8	WANG, et al.; "HMG-1 as a Late Mediator of Endotoxin Lethality in Mice", American Association for the Advancement of Science, U.S.; Vol. 285, July 9, 1999, Pages 248-251, XP002940163.	
	11	YANG HUAN, et al.; "HMGB1 as a Cytokine and Therapeutic Target", Journal of Endotoxin Research, Vol. 8, No. 8, Pages 460-472, XP00302030.	
solh	12	SCAFFIDI PAOLA, et al., "Release of Chromatin Protein HMGB1 by Necrotic Cells Triggers Inflammation", NATURE (London), Vol. 418, no. 6894, July 11, 2002, Pages 191-195, XP009020930.	
1	14	YANG R, et al.; "Ethyl Pyruvate Modulates Inflammatory Gene Expression in Mice Subjected to Hemorrhagic Shock", American Journal of Physiology: Gastrointestinal and Liver Physiology, American Physiological Society, U.S., Vol. 283, 2002, Pages G212-G221, XP008019310.	
1	15	SIMS C A, et al.; "Ringer's Ethyl Pyrulvate Solution Ameliorates Ischemia/ Reperfusion-Induced Intestinal Mucosel Injury in Rats", Critical Care Medicine, Williams and Wilkings Company, Baltimore, MA, U.S., Vol. 29, No. 8, 2001, Pages 1513-1518, XP008019328	

Examiner Signature Bure D. Hurran Date 3/30/06
--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to piace a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.